This prospective study sought to evaluate the healing quality of implanted ultraporous β-tricalcium phosphate sown with expanded autologous mesenchymal stromal cells (MSCs) into femoral defects during revision hip arthroplasty. A total of 37 osseous defects in 37 patients were treated and evaluated concerning bone regeneration. Nineteen subjects received β-tricalcium phosphate graft material serving as a carrier of expanded autologous MSCs (the trial group A), nine subjects received β-tricalcium phosphate graft material only (the study group B) and nine subjects received cancellous allografts only (the control group C). Clinical and radiographic evaluations were scheduled at 6 weeks, 3, 6, and 12 months post-operatively, and performed at the most recent visit as well. All observed complications were recorded during follow-up to assess the use of an ultraporous β-tricalcium phosphate synthetic graft material combined with expanded MSCs in bone defect repair. The resulting data from participants with accomplished follow-up were processed and statistically evaluated with a Freeman-Halton modification of the Fischer's exact test, a P < 0.05 value was considered to be significant. Whereas no significant difference was observed between the trial group A with β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs and control group C with cancellous impaction allografting in terms of the bone defect healing, significant differences were documented between the study group B with β-tricalcium phosphate graft material only and control group C. Regarding adverse effects, six serious events were recorded during the clinical trial with no causal relationship to the cell product. β-tricalcium phosphate synthetic graft material serving as a carrier of expanded autologous MSCs appears safe and promotes the healing of bone defects in a jeopardized and/or impaired microenvironment. This clinical trial was registered at the EU Clinical Trials Register before patient recruitment (Registration number: EudraCT number 2012-005599-33; Date of registration: 2013-02-04).

Department of Medical Biophysics Charles University Faculty of Medicine Hradec Králové Czech Republic

Department of Oncology and Radiotherapy Charles University Faculty of Medicine Hradec Králové Czech Republic

Department of Orthopaedic Surgery University Hospital Hradec Králové Czech Republic

Department of Radiobiology Faculty of Military Health Sciences in Hradec Králové University of Defence in Brno Czech Republic

Department of Radiology University Hospital Hradec Králové Czech Republic

Institute of Experimental Medicine Academy of Sciences of the Czech Republic Prague Czech Republic

Tissue Bank University Hospital Hradec Králové Czech Republic

Zobrazit více v PubMed

Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91(1):128–133. PubMed

Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89(4):780–785. PubMed

Della Valle CJ, Paprosky WG. The femur in revision total hip arthroplasty evaluation and classicication. Clin Orthop Relat Res. 2004;420:55–62. PubMed

Mayle RE, Paprosky WG. Masive bone loss. Allograft-prosthetic composites and beyond. J Bone Joint Surg Br. 2012;94(11):61–64. PubMed

Hartman C, Garvin K. Femoral fixation in revision total hip arthroplasty. J Bone Joint Surg Am. 2011;93(24):2311–2322. PubMed

Buttaro M, Araujo GS, Araujo ES, Comba F, Piccaluga F. Viability of impacted bone allografts under metal mesh at the calcar in revision surgery of the hip. J Bone Joint Surg.Br. 2008;90(2):228–231. PubMed

Board TN, Rooney P, Kearney JN, Kay PR. Impaction allografting in revision total hip replacement. J Bone Joint Surg Br. 2006;88(7):852–857. PubMed

Linder L. Cancellous impaction grafting in the human femur: histological and radiographic observations in 6 autopsy femurs and 8 biopsies. Acta Orthop Scand. 2000;71(6): 543–552. PubMed

Korompilias AV, Paschos NK, Lykissas MG, Kostas-Agnantis I, Vekris MD, Beris AE. Recent updates of surgical techniques and applications of free vascularized fibular graft in extremity and trunk reconstruction. Microsurgery. 2011;31(3):171–175. PubMed

Catagni MA, Guerreschi F, Lovisetti L. Distraction osteogenesis for bone repair in the 21st century: lessons learned. Injury. 2011;42(6):580–586. PubMed

Masquelet A, Begue T. The concept of induced membrane for reconstruction of long bone defects. Orthop Clin North Am. 2010;41(1):27–37. PubMed

Lammens J, Laumen A, Delport H, Vanlauwe J. The Pentaconcept in skeletal tissue engeneering. A combined approach for the repair of bone defects. Acta Orthop Belg. 2012;78(5):569–573. PubMed

Quarto R, Masrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M. Repair of large bone defects with the use of autologous bone marrow stroma cells. N Eng J Med. 2001;344(5):385–386. PubMed

Marcacci M, Kon E, Moukhachev V, Kutepov S, Quarto R, Mastrogiacomo M, Cancedda R. Stem cells associated with macroporous bioceramics for long bone repair: 6-to 7-year outcome of a pilot clinical study. Tissue Eng. 2007;13(5):947–955. PubMed

Šponer P, Filip S, Kučera T, Brtková J, Urban K, Palička V, Kočí Z, Syka M, Bezrouk A, Syková E. Utilizing autologous multipotent mesenchymal stromal cells and β-tricalcium phosphate scaffold in human bone defects: a prospective, controlled feasibility trial. Biomed Res Int. 2016;2016:2076061. PubMed PMC

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prokop D, Horowitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular therapy position statement. Cytotherapy. 2006;8(4):315–317. PubMed

Gie GA, Linder L, Ling RS, Simon JP, Slooff TJ, Timperley AJ. Impacted cancellous allografts and cement for revision total hip arthroplasty. J Bone Joint Surg Br. 1993;75(1):14–21. PubMed

Harris WH. Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am. 1969;51(4):737–755. PubMed

D’Antonio J, McCarthy JC, Bargar WL, Borden LS, Cappelo WN, Collis DK, Steinberg ME, Wedge JH. Classification of femoral abnormalities in total hip arthroplasty. Clin Orthop Relat Res. 1993;(296):133–139. PubMed

Brooker AE, Bowerman JW, Robinson RA, Riley LH. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am. 1973;55(8):1629–1632. PubMed

Freeman GH, Halton JH. Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika. 1951;38(1–2):141–149. PubMed

Corten K, Macdonald S, Mccalden R, Bourne R, Naudie DR. Results of cemented femoral revisions for periprosthetic femoral fractures in the elderly. J Arthroplasty. 2012;27(2):220–225. PubMed

Noble PC, Alexander JW, Lindahl LJ, Yew DT, Granberry WM, Tullos HS. The anatomic basis of femoral design. Clin Orthop Relat Res. 1988;235:148–165. PubMed

Weiss RJ, Beckman MO, Enocson A, Schmalholz A, Stark A. Minimum 5-year follow-up of a cementless, modular, tapered stem in hip revision arthroplasty. J Arthroplasty. 2011;26(1):16–23. PubMed

Blom AW, Grimm B, Miles AW, Cunningham JL, Learmonth ID. Subsidence in impaction grafting: the effect of adding a ceramic bone graft extender to bone. Proc Inst Mech Eng H. 2002;216(4):265–270. PubMed

Levine B, Sporer S, Poggie R, Della Valle CJ, Jacobs JJ. Experimental and clinical performance of porous tantalumin orthopaedic surgery. Biomaterials. 2006;27(27):4671–4681. PubMed

Manassero M, Paquet J, Deschepper M, Viateau V, Retorillo J, Bensidhoum M, Logeart-Avramoglou D, Petite H. Comparison of survival and osteogenic ability of human mesenchymal stem cells in orthotopic and ectopic sites in mice. Tissue Eng Part A. 2016;22(5–6):534–544. PubMed

Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, Lee MS, Kwon CH, Joh JW, Kim S, Kim KW. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation. 2010;89(5):509–517. PubMed

Gnecchi M, Danieli P, Cervio E. Mesenchymal stem cell therapy for heart disease. Vasc Pharmacol. 2012;57(1):48–55. PubMed

Bortolotti F, Ukovich L, Razban V, Martinelli V, Ruozi G, Pelos B, Dore F, Giacca M, Zacchigna S. In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure. Stem Cell Reports. 2015;4(3):332–339. PubMed PMC

Alberton GM, High WA, Morrey BF. Dislocation after revision total hip arthroplasty: an analysis of risk factors and treatment options. J Bone Joint Surg Am. 2002;84–A(10):1788–1792. PubMed

Lamagni T. Epidemiology and burden of prosthetic joint infections. J Antimicrob Chemother. 2014;69(suppl 1):i5–i10. PubMed

Berstock JR, Beswick AD, Lenguerrand E, Whitehouse MR, Blom AW. Mortality after total hip replacement surgery: a systematic review. Bone Joint Res. 2014;3(6):175–182. PubMed PMC

Memtsoudis SG, Besculides MC, Gaber L, Liu S, Gonzáles Della Valle A. Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study. Int Orthop. 2009;33(6):1739–1745. PubMed PMC

Mohamed NN, Barrett JA, Katz JN, Phillips CB, Losina E, Guadagnoli E, Harris WH, Poss R, Baron JA. Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am. 2003;85(1):27–32. PubMed

Beswick A, Blom AW. Bone graft substitutes in hip revision surgery: a comprehensive overview. Injury. 2011;42(2):S40–S46. PubMed

Amanatullah DF, Howard JL, Siman H, Trousdale RT, Mabry TM, Berry DJ. Revision total hip arthroplasty in patients with extensive proximal femoral bone loss using a fluted tapered modular femoral component. Bone Joint J. 2015;97(3):312–317. PubMed

Damron TA, Lisle J, Craig T, Wade M, Silbert W, Cohen H. Ultraporous β-tricalcium phosphate alone or combined with bone marrow aspirate for benign cavitary lesions. J Bone Joint Surg Am. 2013;95(2):158–166. PubMed

Roth TD, Maertz NA, Parr JA, Buckwalter KA, Choplin RH. CT of the hip prosthesis: appearance of components, fixation, and complications. Radiographics. 2012;32(4):1089–1107. PubMed

Nauth A, Schemitsch EH. Stem cells for the repair and regeneration of bone. Indian J Orthop. 2012;46:19–21. PubMed PMC